SR-142,948
 | |
| IUPAC ime | |
|---|---|
2-([5-(2,6-dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino)adamantane-2-carboxylic acid | |
| Identifikatori | |
| CAS broj | 184162-64-9 |
| PubChem | CID 5311451 |
| IUPHAR/BPS | 1580 |
| ChemSpider | 4470937  |
| Hemijski podaci | |
| Formula | C39H51N5O6 |
| Molarna masa | 685.850 g/mol |
| |
| |
SR-142,948 je lek koji se koristi u naučnim istraživanjima. On pripada grupi nepeptidnih antagonista selektivnih za neurotenzinske receptore, mada nije selektivan za specifični tip tog receptora.[1] On je korišten u izučavanju uloge neurotenzina u regulaciji aktivnosti dopaminskog receptora[2][3][4][5] i glutamatne signalizacije u mozgu.[6][7] U životinjskim studies SR-142,948 blokira efekte stimulanata,[8] kao što je MDMA.[9]
Reference[уреди | уреди извор]
- ^ Nalivaiko E, Michaud JC, Soubrié P, Le Fur G (1998). „Electrophysiological evidence for putative subtypes of neurotensin receptors in guinea-pig mesencephalic dopaminergic neurons”. Neuroscience. 86 (3): 799—811. PMID 9692718. doi:10.1016/S0306-4522(98)00084-0.
- ^ Alonso R, Gnanadicom H, Fréchin N, Fournier M, Le Fur G, Soubrié P (1999). „Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain”. The European Journal of Neuroscience. 11 (3): 967—74. PMID 10103090. doi:10.1046/j.1460-9568.1999.00506.x.[мртва веза]
- ^ Matsuyama S, Higashi H, Maeda H, Greengard P, Nishi A (2002). „Neurotensin regulates DARPP-32 thr34 phosphorylation in neostriatal neurons by activation of dopamine D1-type receptors”. Journal of Neurochemistry. 81 (2): 325—34. PMID 12064480. doi:10.1046/j.1471-4159.2002.00822.x.[мртва веза]
- ^ Leonetti M, Brun P, Sotty F, Steinberg R, Soubrié P, Bert L, Renaud B, Suaud-Chagny MF (2002). „The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area”. Naunyn-Schmiedeberg's Archives of Pharmacology. 365 (6): 427—33. PMID 12070755. doi:10.1007/s00210-002-0574-6.
- ^ Panayi F, Colussi-Mas J, Lambás-Señas L, Renaud B, Scarna H, Bérod A (2005). „Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization”. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30 (5): 871—9. PMID 15637639. doi:10.1038/sj.npp.1300638.
- ^ Matsuyama S, Fukui R, Higashi H, Nishi A (2003). „Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: involvement of glutamate signalling”. The European Journal of Neuroscience. 18 (5): 1247—53. PMID 12956723. doi:10.1046/j.1460-9568.2003.02859.x.[мртва веза]
- ^ Yin HH, Adermark L, Lovinger DM (2008). „Neurotensin reduces glutamatergic transmission in the dorsolateral striatum via retrograde endocannabinoid signaling”. Neuropharmacology. 54 (1): 79—86. PMC 2697967
. PMID 17675102. doi:10.1016/j.neuropharm.2007.06.004.
- ^ Reynolds SM, Geisler S, Bérod A, Zahm DS (2006). „Neurotensin antagonist acutely and robustly attenuates locomotion that accompanies stimulation of a neurotensin-containing pathway from rostrobasal forebrain to the ventral tegmental area”. The European Journal of Neuroscience. 24 (1): 188—96. PMID 16882016. doi:10.1111/j.1460-9568.2006.04791.x.
- ^ Marie-Claire C, Palminteri S, Romualdi P, Noble F (2008). „Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice”. Neuropharmacology. 54 (7): 1107—11. PMID 18410947. doi:10.1016/j.neuropharm.2008.03.001.
Spoljašnje veze[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
